Project Grant R21DA063771
Award Date 8/15/26
Completion Date 7/31/28
Dollars Obligated $410K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
- The National Institute on Drug Abuse awarded the University of Alabama at Birmingham $661,299 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research into opioid use disorder mechanisms and potential therapeutic targets. The research, titled "A Novel Cellular and Circuit Target for Opioids," investigates a transcriptionally distinct neuronal population in the nucleus accumbens that expresses high levels of the mu opioid receptor...
- The National Institute on Drug Abuse awarded the University of Alabama at Birmingham $1.788 million on April 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a Type 1 hybrid effectiveness-implementation randomized controlled trial testing a remote intervention to prevent overdose among people who use stimulants and opioids. The award funds the R61 phase of a two-phase study designed to isolate the independent impact of remote education on overdose outcomes...
- The National Institute on Drug Abuse awarded the University of Alabama at Birmingham $157,016 on November 30, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate tabernanthalog (TBG) as a dual treatment for chronic pain and opioid use disorder. The research addresses the co-morbidity of opioid use disorder and chronic pain, conditions often treated with opioid-based therapies that can exacerbate both conditions. The project investigates TBG, a...
- The National Institute on Drug Abuse awarded the University of Pittsburgh $701,569 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on the use and effectiveness of medications for opioid use disorder in older adults with multimorbidity. The award funds quantitative studies of Medicare and Veterans Health Administration enrollees with diagnosed opioid use disorder and a qualitative study of older adults with opioid use disorder and...
- This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $844,475 to the University of Alabama at Birmingham (UAB) to test a bundled intervention aimed at increasing treatment uptake for patients with opioid use disorder (OUD) and nonfatal opioid overdoses after emergency department (ED) discharge. The proposed intervention combines telehealth, peer support, buprenorphine prescribing, and linkage to...
- The National Institute on Drug Abuse awarded Albert Einstein College of Medicine $199,584 on March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support a five-year mentored research and career development project establishing Dr. Michele Buonora as an independent clinician investigator in implementation science. The project conducts a hybrid type 1 effectiveness-implementation study examining patient-controlled analgesia (PCA) for acute pain management in...
- The National Institute on Drug Abuse awarded the University of Pittsburgh $945,601 under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 30, 2025, for the Personalized Methadone Treatment (PROMOTE) study implementing shared decision making in opioid treatment programs. The project adapts implementation facilitation—a bundle of preparation, implementation, and sustainment strategies—to support systematic shared decision making (SDM) implementation within opioid treatment...
- The National Institute on Drug Abuse awarded The Trustees of the University of Pennsylvania $100,228 on January 14, 2027, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct data science-driven analysis of opioid use trajectories among opioid-naive individuals following arthroplasty. The recipient will develop a prediction model to identify patients at risk for new persistent opioid use (NPOU)—prolonged opioid exposure beyond the typical three-month post-operative...
- The National Institute on Drug Abuse awarded Vanderbilt University Medical Center $825,492 on July 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a comparative analysis of buprenorphine dosing and clinical outcomes across pregnant and non-pregnant populations with opioid use disorder. The research addresses the gap between clinical evidence and practice in medication-assisted treatment during pregnancy. The study assesses national and state-level...
- The National Institute on Drug Abuse awarded the University of Utah $1,442,744 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct the Co-Use of Opioids and Alcohol Prevention Study (COAPS) 2.0. The award funds a hybrid type-2 implementation effectiveness study designed to scale an alcohol-targeted brief intervention-medication therapy management (ABI-MTM) intervention across community pharmacy settings. The study will execute a three-pronged...